[Corrections] Correction to Lancet Oncol 2023; 24: 1002–17

Leal T, Kotecha R, Ramlau R, et al. Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. Lancet Oncol 2023; 24: 1002–17—In this Article, a footnote was added to table 3, which reads “In the immune checkpoint inhibitor subgroup, one additional patient had an adverse event (atrial fibrillation) of unknown grade and two additional patients had respiratory tract infection adverse events of unknown grade.” The appendix was also updated.